Get started
EVAX – AI Cancer Vaccine Momentum Flag | Moonshot SetupWe're watching NASDAQ:EVAX for a potential moonshot breakout following strong momentum, low float dynamics, and fundamental catalysts tied to their AI-powered cancer vaccine program. Setup Summary: Sector: Biotech / AI immunotherapy Market Cap: ~$15M (micro float) News Catalyst: Q1 earnings beat + EVX-01 Phase 2 dosing Analyst Target: $13 avg → +450% potential Technical Picture (Daily + 15m): Breakout over $2.20 zone with clean base RSI breakout from 65 → 80 MACD crossover + rising volume EMA9 & EMA20 support structure Pre-market highs: $2.37 (watch for breakout + hold) Trade Levels: Entry Trigger: Above $2.40 with confirmation TP1: $2.80 TP2: $3.30 SL: $2.15 (flag low) Optional Fibo Re-Entry: $2.25–$2.30 zone Notes: Float under pressure = high squeeze potential Fundamentals align with technicals → this is what we hunt for Small size advised – this is a moonshot, not a base trade “We don’t chase hype – we ride structure.”
NASDAQ:EVAXLong
by DaddyDjole
MAXHEALTHCARE - Could Breakout from DTHMAXHEALTHCARE has resistance weakening on the Daily charts and may give a breakout with good volume in coming days. The target of this pattern signals an upside potential of 15% from the current price level in the medium term. The stock is trading above its 50- and 100-day exponential moving averages (EMAS) recently. Look for the range to more than 1.5X, and the Volume 1.5X the average. CMP- Rs. 1149 Entry Price- 1200 Target Price- Rs1380 (15% upside) SL- 1142 Need to wait for the entry to get triggered. Disclaimer: This is not a buy/sell recommendation. For educational purpose only. Kindly consult your financial advisor before entering a trade.
NSE:MAXHEALTHLong
by ashutoshanand30
DEEPAK FERTILIZER - Breaking Out in DTF, New ATHDEEPAKFERT has resistance weakening on the Daily charts and has given a breakout with good volume and making a new ATH. The target of this pattern signals an upside potential of 20% from the current price level in the medium term. The stock is trading above its 50- and 100-day exponential moving averages (EMAS). The range is more than 1.5X, and the Volume is also 1.5X the average. CMP- Rs. 1449.80 Target Price- Rs. 1650 (~20% upside) SL- 1356 Disclaimer: This is not a buy/sell recommendation. For educational purpose only. Kindly consult your financial advisor before entering a trade.
NSE:DEEPAKFERTLong
by ashutoshanand30
Profit Raiders’ Guide to Conquering AMAZON Stock!Hello, Wealth Warriors! 🌟 Stock market adventurers, let’s embark on a thrilling quest to dominate AMAZON stock with our cunning Raider Trading Strategy! 🗡️📈 Fueled by razor-sharp technical analysis and robust fundamental insights, this plan targets high-reward zones while dodging market traps. Follow the long-entry map, aim for the golden profit zone, and stay vigilant for overbought signals, consolidation, or bearish ambushes that could shift the trend. 🐻🔍 Secure your gains and celebrate your victory! 🎉 Entry 📈 The treasure chest is wide open! 🏰 Seize the bullish momentum at the current price of $206.02—your adventure begins! For precision, set Buy Limit orders on a 15 or 30-minute chart for pullback entries, targeting a retest of recent highs ($206.69) or lows ($202.19). Stop Loss 🛑 📍 Place your Raider Stop Loss at the recent swing low ($196.00) on a 4-hour chart for day trades. Adjust based on your risk tolerance, position size, and number of trades to stay in control. 🛡️ Target 🎯 Set your sights on $217.00 or exit early to lock in your profits! 💸 Refer to the finance card above for price trends. Scalpers, Stay Sharp! 👀 Focus on quick long-side trades. Large accounts? Strike now! Smaller portfolios? Join swing traders for the raid. Use a trailing stop to safeguard your gains as the stock moves. 🧲💰 AMAZON Stock Market Insights 📊 AMAZON is charging bullish, driven by strong fundamentals. 📈 Dive into earnings reports, macroeconomic trends, geopolitical events, market sentiment, sector correlations, and future price projections for a complete view. As of May 28, 2025, at 12:04 AM EST (UTC-5), the stock’s momentum is supported by a market cap of $2.17 trillion and a year-to-date high of $242.52. Stay informed! 🔗 ⚠️ Trading Alert: News & Risk Management 📰 Market-moving news can strike fast! Protect your gains: Avoid opening trades during major news events. Use trailing stops to secure profits and minimize losses. 🚫 Join the Raid! 💥 Support our battle plan—smash the Boost Button! 🚀 Let’s conquer the market with the Raider Trading Strategy and stack profits like true stock market legends. 💪🤝 Prepare for the next adventure, raiders! 🤑⚔️🎉
NASDAQ:AMZNLong
by Thief_Trader
Blackberry Update-Review - Let the Bulls drive in !In the previous analysis, we observed the formation of an impulsive 1-2-3-4-5 structure of a cycle according to Elliott Wave Theory, which was invalidated by a downside breakout (caused by tariff-related uncertainties). After a period of consolidation, during which trading was mostly driven by algorithms, it now appears that technical analysis has once again become relevant. In this study, we examine the targets of an Minor-degree impulsive wave, typically lasting up to 6 months, as well as those of a Intermediate-degree wave, which can span 2–3 years and is considered to have started in November 2024. These are probabilistic scenarios, and it is important to remember that Elliott Waves were originally developed for analyzing stock market indices. Personally, I believe Blackberry is the most undervalued tech stock on the market!
NYSE:BBLong
by Tesi_Daniela_Radice
IPI - Fertilizer Trade: A Forgotten Play, Geopolitical upsideWhenever a resolution to the Russia-Ukraine war materializes, agricultural restoration will be one of the first and most critical steps, not just for Ukraine's battered fields but also for Russia's export infrastructure. Both countries are central to global wheat markets, and reviving output means ramping up fertilizer usage, especially potash. That sets the stage for renewed interest in fertilizer producers. Potash, also known as potassium chloride, is an important nutrient for plants. It helps them resist drought, strengthens their roots, and increases crop yields. Unlike more energy-intensive nitrogen fertilizers, potash supply is concentrated and not easily ramped up. Belarus and Russia are among the top 10 world potash exporters, but sanctions and supply chain bottlenecks have impacted their volumes. Ukraine will need to import significant amounts of potash to rebuild its ag base. Global potash demand could rise sharply as post-war reconstruction efforts kick in, and that makes Western suppliers a critical piece of the puzzle The market may not be pricing in this recovery narrative just yet. Fertilizer stocks popped in 2022, but most have been rangebound or sold off since as supply chains stabilized and the commodity cycle cooled off. But structurally, if global potash demand starts ramping again, especially from a fresh buyer like Ukraine coming back, the upside case for U.S.-based producers becomes clearer. Macro themes like agricultural recovery after war are slow-building but often explosive once recognized. The fertilizer story is one of them. If you're positioning ahead of that curve, it's not just about trading. It's also about recognizing that geopolitical peace, when it comes, won't just be about diplomacy. It'll be about digging back into the soil and starting over. Intrepid Potash may be one of the most overlooked names in the market right now. It is tucked away in the fertilizer sector, has low volume, and is not hyped. But that quiet tape hides an interesting setup. After a boom-bust cycle following the 2022 commodity shock, IPI has been grinding through a long consolidation. Now, with potash prices stabilizing and geopolitical risk still unresolved, the stock is showing early signs of an uptrend. And with options cheap and sentiment nonexistent, this could be a classic contrarian long. 2022: IPI surged alongside fertilizer peers after Russia's invasion of Ukraine sparked global fears of food insecurity and disrupted potash supply chains. 2023–2024: The stock gave up those gains as: Central banks hiked aggressively, capping inflation-linked trades. Potash prices corrected from panic highs. Broader commodity sentiment turned defensive. Now (Mid-2025): IPI is starting to build out around long-term support. Price action is tightening, and early momentum signals are starting to flash. This isn't a runaway rally yet, but it's building the right kind of structure. Call options with a ~$45-$50 target expiring December (can also use call spreads) Option premiums are still cheap, reflecting low implied volatility and a market because nobody 'in their right mind' is looking at this yet. If Russia-Ukraine negotiations resume or if even partial de-escalation happens, the market may quickly reprice ag rebuild stories. Fertilizer demand from Ukraine could spike, and with Belarusian and Russian supply still under partial sanctions, Western producers like IPI could benefit disproportionately. If the Fed signals that it's near the end of its tightening cycle or even hints at cuts in late 2025, rate-sensitive commodity equities could start to re-rate higher. That would relieve pressure on capex-intensive names like IPI. Global potash prices are off their highs but showing signs of stabilization. If demand forecasts pick up, prices don't need to move explosively higher, just holding firm or ticking higher could expand margins and renew investor interest & sentiment  With few traders active in IPI's options, implied volatility remains low. Any volume-driven breakout (or narrative shift) could trigger a fast repricing. Think of this as a "volatility catch-up" play in addition to a directional one.
NYSE:IPILong
by RomanoRnr
Roche Strengthens Its Bet Against the “Superbug”By Ion Jauregui – Analyst at ActivTrades Zosurabalpin: A New Hope Against Antimicrobial Resistance Swiss pharmaceutical giant Roche (SWX: ROG) has just taken a major step forward in the fight against bacterial resistance: its new antibiotic zosurabalpin is entering Phase 3 clinical trials. The compound targets acinetobacter baumannii, a highly resistant Gram-negative bacterium that causes serious infections such as pneumonia and sepsis, with mortality rates ranging from 40% to 60%, according to Larry Tsai, Chief Medical Officer at Genentech, Roche’s U.S. subsidiary. The clinical trial is set to begin in late 2025 or early 2026, involving approximately 400 patients across more than 100 international sites. If successful, zosurabalpin would become the first new class of antibiotics targeting Gram-negative bacteria in over 50 years, marking a historic milestone in pharmaceutical development. Strategic Return to the Antibiotics Arena After stepping away from antibiotic research for several years, Roche re-entered the field in the past decade, just as the WHO warned of the growing threat of antimicrobial resistance, which could lead to up to 10 million deaths annually by 2050. This move underlines Roche’s renewed commitment to innovation in critical areas of global health. Economic Context and Market Position So far in 2025, Roche has delivered mixed financial results. In its first-quarter report, revenue grew 2% year-on-year, driven by its diagnostics division, while its oncology segment remains solid. However, margin pressures persist, and the biotech landscape remains fiercely competitive. On the stock market, Roche shares have remained relatively stable around 250 Swiss francs, with investors showing caution toward the company’s pace of innovation in the post-pandemic era. The move to Phase 3 for zosurabalpin may shift that perception and position Roche as a pioneer in a long-overlooked segment of the pharmaceutical industry: next-generation antibiotics. Technical Analysis The stock has been trading within a range between 249.6 and 303.2 francs, peaking at 323.6 francs in late March, followed by a sharp correction that found support at 244 francs in early April. The current point of control lies slightly below the midpoint of the range at 263 francs. The RSI sits at 49.11%, indicating a relatively balanced momentum. Moving average crossovers suggest a potential price correction, as the 200-day average recently crossed below the 50-day average. Conclusion Roche’s latest advance could not only save thousands of lives but also restore the company’s leadership in the fight against infectious diseases. If all goes according to plan, zosurabalpin could be available before 2030, ushering in a new era in modern medicine. ******************************************************************************************* The information provided does not constitute investment research. The material has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and such should be considered a marketing communication. All information has been prepared by ActivTrades ("AT"). The information does not contain a record of AT's prices, or an offer of or solicitation for a transaction in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. Any material provided does not have regard to the specific investment objective and financial situation of any person who may receive it. Past performance is not reliable indicator of future performance. AT provides an execution-only service. Consequently, any person acting on the information provided does so at their own risk.
SIX:ROShort
by ActivTrades
Technical Analysis of Hindustan Zinc - Buy & HoldLet's analyze Hindustan Zinc (HINDZINC) based on the chart. Current Status and Observations: Chart Type: Weekly Candlestick Chart. Current Price: Approximately INR 455.30 (as per the blue box on the right). Recent Action: The stock has recently broken above a "Monthly Breakout @408.90" and retested "Retest after Monthly Breakout @428.75". This indicates a bullish reversal or continuation from a support level. RSI (Relative Strength Index): The RSI is at 47.39, which is in a neutral zone but showing an upward trend, suggesting increasing momentum. Volume: The volume bar for the current week appears to be significant, supporting the recent upward movement. Resistance Levels: Weekly Resistance @482.50 Daily Target TP1 @516.50 4H Target TP2 @562.50 3H Target TP3 @590.00 Buy Price and Targets: Given the recent breakout and retest, along with the increasing RSI, Hindustan Zinc appears to be in a favorable position for a buy. Optimal Buy Zone: The ideal buy zone would have been closer to the retest level of INR 428.75. However, given the current price, a buy at current levels (around INR 455 - 460) is still viable, provided the breakout holds. Traders might consider buying on minor dips towards INR 445-450 if they occur. Near-Term Targets: Target 1 (Short-term/Swing Trade): INR 482.50 (Weekly Resistance). This is the immediate hurdle. Target 2 (Mid-term): INR 516.50 (Daily Target TP1). Once Target 1 is cleared, this becomes the next logical objective. Target 3 (Mid to Long-term): INR 562.50 (4H Target TP2). This level offers a significant upside potential. Target 4 (Longer-term/Aggressive): INR 590.00 (3H Target TP3). This is the highest target indicated and suggests a strong upward trajectory if momentum continues. Position and Duration: Buy Position: Yes, initiate a buy. The chart indicates a constructive setup. Hold Position with Duration: For Short-Term Traders (Swing Trading): Hold for a duration of 1 to 4 weeks aiming for Target 1 (INR 482.50) and potentially Target 2 (INR 516.50). Monitor price action closely at resistance levels. For Mid-Term Investors: Hold for a duration of 1 to 3 months aiming for Target 3 (INR 562.50). For Long-Term Investors: Hindustan Zinc is a fundamental company, and if the broader market and commodity prices remain supportive, it could be a longer-term hold. For the targets shown on the chart, a duration of 3 to 6 months+ could be considered for reaching Target 4 (INR 590.00) or beyond. Important Considerations and Risk Management: Stop Loss: A crucial part of any trade is a stop loss. A logical stop loss could be placed just below the retest level or the monthly breakout level, for example, around INR 420-425. A tighter stop could be just below the current week's low if you have a shorter time horizon. Volume Confirmation: Continue to monitor volume. Strong buying interest confirmed by rising volume is a positive sign. Global Commodity Prices: Hindustan Zinc's performance is highly correlated with global zinc and other metal prices. Keep an eye on commodity market trends. Company Fundamentals: While this analysis is purely technical, it's always advisable to have a basic understanding of the company's fundamentals and any upcoming news or events. Market Volatility: The market can be volatile. Be prepared for fluctuations and adjust your strategy accordingly. In summary, Hindustan Zinc presents a compelling technical setup for a buy, with clear targets in the near to mid-term. However, proper risk management with a defined stop loss is paramount. Disclaimer: This is not financial advice. Always conduct your own analysis before trading. We are not responsible for your loss. Do your own research before buying this stock.
NSE:HINDZINCLong
by ForexTrader4all
Buy Idea for MQG (Macquarie Group Ltd)📈 Buy Idea – MQG.ASX 🔹 Entry: $210.49 🔹 Stop: $201.80 (Risk ~4.1%) 🔹 Target 1: $227.50 🔹 Target 2: $238+ 🔹 R:R: ~1:3 Setup: – Tight sideways consolidation near 50MA – Strong volume support near $205 zone – Bullish engulfing candle into breakout zone – Sector strength: Financials stabilizing post RBA cut – Clean technical base + upside momentum potential Why It Works: 🔸 High-quality name with macro tailwind (lower rates = banking boost) 🔸 Tight risk with upside if it breaks out above $215 🔸 Good institutional interest & dividend tailwind 🚨 Trigger Alert: Add above $215 for momentum confirmation 🔔 Monitor closely for follow-through above resistance DISCLAIMER : The content and materials featured are for your information and education only and are not attended to address your particular personal requirements. The information does not constitute financial advice or recommendation and should not be considered as such. Risk Management is Your Shield! Always prioritise risk management. It’s your best defence against losses.
ASX:MQGLong
by Gihanhemachandra
Brainbees Solutions Ltd view for Intraday 28th May #FIRSTCRY RBrainbees Solutions Ltd view for Intraday 28th May #FIRSTCRY Resistance 360 Watching above 361 for upside momentum. Support area 350 Below 355 ignoring upside momentum for intraday Watching below 348 for downside movement... Above 355 ignoring downside move for intraday Charts for Educational purposes only. Please follow strict stop loss and risk reward if you follow the level. Thanks, V Trade Point Resistance 360 Watching above 361 for upside momentum. Support area 350 Below 355 ignoring upside momentum for intraday Watching below 348 for downside movement... Above 355 ignoring downside move for intraday Charts for Educational purposes only. Please follow strict stop loss and risk reward if you follow the level. Thanks, V Trade Point
NSE:FIRSTCRYLong
by vichithra